Dr Eddy Betterman MD
The rollout of Wuhan coronavirus (COVID-19) vaccines in Japan has been delayed due to the country’s insistence on running domestic clinical trials before it approves any vaccine.
The one outstanding condition Japan requires from Moderna, BioNTech-Pfizer, AstraZeneca and several other pharmaceutical companies is that they conduct small clinical trials on Japanese citizens that demonstrate the vaccines are able to generate a similar level of antibodies. These trials must show that the safety and efficacy of the vaccines do not differ. (Related: Suicide spike in Japan linked to coronavirus pandemic; Prevention measures must be implemented immediately, experts warn.)
If these pharmaceutical companies pass Japan’s requirements, vaccinations can start, at the latest, by the end of February. This is three months after some of the earliest vaccine rollouts in the West – notably in the United States and the United Kingdom – and less than five months before the…
View original post 6 more words